news
Diagnosing cancer: new process for identifying biomarkers established
Scientists have established a process for identifying biomarkers for the diagnosis of different types of cancer.
List view / Grid view
Cancer
news
Aprea Therapeutics to collaborate with Memorial Sloan Kettering cancer center
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
news
A new role for an old immune cell may lead to novel therapies
A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
article
Antibodies In-Depth Focus 2017
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
news
Vitamin C effective at targeting cancer stem cells
Vitamin C is up to ten times more effective at stopping cancer cell growth than pharmaceuticals such as 2-DG, according to an article published in Oncotarget
article
Towards systems biomarkers for cancer diagnosis
Cancer is asymptomatic during most of its pathogenesis. It is very difficult to see that a cancer is growing in a person, except for a few self-evident cases such as skin cancer. Its intangibility and year-, if not decade-long progression make cancer hard to diagnose until some symptoms warrant further…
news
£100 million for Cancer Research’s ‘grand challenge’ competition winners
Cancer Research UK announced that four international teams are the first recipients of its global £100m Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
news
Amgen and Immatics to collaborate on bispecific cancer immunotherapies
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
news
Macrophage raises £9 million & acquires immune-oncology technology
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
news
Immunotherapy and gene therapy combination shows promise against brain tumours
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
news
Nanohyperthermia softens tumours to improve treatment
The mechanical resistance of tumours and collateral damage of standard treatments often hinder efforts to defeat cancers.
article
Industrialising organoids for the next generation of drug discovery
New synthetic 3D gel technology for cell culture promises to unlock the potential of ‘mini-organs’ for industrial drug discovery.
news
QGel raises $12 million to grow mini-organs for drug discovery
The biomaterials company QGel has received $12 million to be used to accelerate QGel’s global expansion and broaden the company "organoids" products.
news
Oncology collaboration: Proteros & MSD to find epigenetic target
22 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Proteros has entered into a second research agreement with Merck aimed at developing small molecule compounds against an additional epigenetic target...
article
Rural, poor and sick: The unseen cancer crisis in America
20 October 2016 | By Aaron Yao, PhD, University of Virginia School of Medicine
PhD student Aaron Yao highlights the shocking disparities between rural and urban eastern America and how the odds of cancer survival do not favour the impoverished...
